News
Feed
Events
Feed
News
+ Events
Feed

Immunic AG

  • Land Deutschland

Aktuelle News

20 März 2024

11:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

7 März 2024

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Investor and Scientific Conferences in March

29 Februar 2024

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

22 Februar 2024

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

15 Februar 2024

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

1 Februar 2024

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Investor and Scientific Conferences in February

5 Januar 2024

12:35 Corporate EN

Immunic AG

Corporate
EN

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic, Inc. Announces Private Placement of up to $240 Million

21 November 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis

2 November 2023

11:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

26 Oktober 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Scientific and Industry Conferences in November

16 Oktober 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

15 Oktober 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

11 Oktober 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

9 Oktober 2023

22:01 Corporate EN

Immunic AG

Corporate
EN

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

4 Oktober 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Scientific Conferences in October

6 September 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Industry and Investor Conferences in September

17 August 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

1 August 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Investor and Scientific Conferences in August

29 Juni 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Scientific and Investor Conferences in July

30 Mai 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Scientific and Investor Conferences in June

17 Mai 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

6 Mai 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

4 Mai 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

27 April 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

26 April 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Investor and Scientific Conferences in May

5 April 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

2 März 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Participate in Investor and Scientific Conferences in March

22 Februar 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

9 Februar 2023

12:30 Corporate EN

Immunic AG

Corporate
EN

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Anstehende Events

Keine Events gefunden